RANCHO SANTA MARGARITA, Calif., Aug. 6, 2002 (PRIMEZONE) -- BioCurex Inc. (OTCBB:BOCX) is pleased to announce a strategy to significantly expand its European presence for the marketing of its novel RECAF(tm) technology. The Company has signed a definitive agreement with European Launch Pad (ELP) (www.europeanlaunchpad.com) to facilitate the first stages of a European footprint, which furthers BioCurex's strategic plan to enter the EU. Under the agreement, ELP will undergo extensive research to assess viability and barriers to entry in the market for RECAF(tm) technologies in those EU countries and European countries where BioCurex has no existing marketing arrangements.
BioCurex Inc. (OTCBB:BOCX) is a biotechnology company that has developed patented/proprietary technology in the areas of cancer diagnosis, tumor imaging and therapeutics. The technology identifies a common cancer biomarker or receptor known as RECAF(tm), thereby allowing detection of malignant cancers from blood tests or tissue biopsies. The company develops other uses for RECAF(tm) technology including blood tests and imaging.
On the topic, CEO Paul Slowey stated, "We aim to capitalize on the expertise of ELP to identify specific trends and opportunities in Europe, which may differ from our experience in the domestic markets. We will then utilize ELP's competitive edge to identify specific licensing and / or distribution partners with the necessary qualities to command a market share which will meet the expectations of the Company and its shareholders."
The European market represents a strong potential market for BioCurex, second only to the U.S. market in size. The company will make a decision as to their preferred route of entry on a country-by-country basis once all research and partner profiling has been completed by ELP. This information is due to be published on both the ELP and BioCurex websites within thirty days.
Note:
Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.